

HETEROCYCLES, Vol. 78, No. 12, 2009, pp. 2951 - 2962. © The Japan Institute of Heterocyclic Chemistry
Received, 10th July, 2009, Accepted, 5th October, 2009, Published online, 6th October, 2009
DOI: 10.3987/COM-09-11794

SYNTHESIS OF 6-SUBSTITUTED PURINE DERIVATIVES

Amal Al-Azmi* and K. Anita Kumari

Chemistry Department, Kuwait University, P. O. Box 5969, Safat 13060, Kuwait


*Correspondent e-mail: amal.alazemi@ku.edu.kw

Abstract - Hydroxylamine hydrochloride reacts readily with (5-amino-1-aryl-1*H*-imidazol-4-yl)iminoacetonitriles to furnish 5-amino-1-aryl-*N*-hydroxy-1*H*-imidazole-4-carboxamidines. When a mixture of 5-amino-1-aryl-*N*-hydroxy-1*H*-imidazole-4-carboxamidine and excess of triethyl orthoesters is reacted at room temperature novel purin-6-one oximes are obtained in moderate yields. Further, reaction of formamidines and ethyl acetoacetate with DBU afforded 6-carbamoylpurines. X-Ray analysis carried out on 9-(4-methoxyphenyl)-2-methyl-9*H*-purine-6-carboxamide monohydrate confirmed its structure. Diazotization of [5-amino-1-(4-methoxyphenyl)-1*H*-imidazol-4-yl]iminoacetonitrile in the presence of an excess of sodium nitrite and concentrated HCl gave 4-carboxy-5-chloro-1-(4-methoxyphenyl)imidazolidinium chloride *via* nucleophilic aromatic substitution reaction. However, (1-aryl-5-hydroxy-1*H*-imidazol-4-yl)-iminoacetonitrile is obtained as product when (5-amino-1-aryl-1*H*-imidazol-4-yl)-iminoacetonitriles (Ar = 4-MeC₆H₄ and Ar = 4-ClC₆H₄) were the reactants. The structure of 4-carboxy-5-chloro-1-(4-methoxyphenyl)imidazolidinium chloride was also established by X-ray analysis.

INTRODUCTION


Purines are an important class of heterocycles because of their significant role as biologically active compounds.¹⁻¹² Generally, their activity depends mainly on the type and position of substituents on the ring, and several reports in the last decade described various methods to synthesize a wide range of purine derivatives.¹³⁻²³ As a result, the search for new synthetic approaches to prepare purines with a wide variety of substituents on either or both rings is continuing. In our research group, we have been investigating the utility of both formamidines **1** and imidazoles **2** as precursors to find new facile synthetic methods to prepare novel fused nitrogen heterocycles such as imidazole derivatives, purines, 6-carbamoylpurines and pyrimido[5,4-*d*]pyrimidines. The literature reports describe many synthetic

procedures to prepare 6-substituted purines starting from either formamidines **1** or imidazoles **2**. The use of both compounds as versatile precursors to 6-substituted purines and other nitrogen heterocycles is increasing.¹⁶⁻²¹ Conversion of the active cyanoformimidoyl unit in imidazole **2** into a new nucleophilic reactive site could be used for further transformations.



RESULTS AND DISCUSSION


Addition of hydroxylamine hydrochloride (5 equiv.) to a suspension of (5-amino-1-aryl-1*H*-imidazol-4-yl)iminoacetonitrile **2a** (Ar = 4-MeOC₆H₄) or **2b** (Ar = 4-MeC₆H₄) in ethanol and stirring the mixture overnight at room temperature led to the isolation of white crystalline solids identified as 5-amino-*N*-hydroxy-1-aryl-1*H*-imidazole-4-carboxamidine **4a** (Ar = 4-MeOC₆H₄) and **4b** (Ar = 4-MeC₆H₄). Both imidazoles were used as intermediates and reacted with triethyl orthoesters. When a suspension of imidazole **4a** and triethyl orthoformate was refluxed, purine **5a** was isolated (48%) (**Scheme 1**). When the same reaction was carried out using triethyl orthoacetate, complete decomposition of the reaction mixture took place. However, stirring the mixture at room temperature for 18 hours afforded the product **5b** (45%). When a mixture of imidazole **4a** and an excess of triethyl orthoformate was stirred at room temperature for 18-20 hours, the yield of **5a** increased (60%).



Scheme 1

It is assumed that hydroxylamine initially adds to substrate **2** to yield intermediate **3** which then loses HCN to furnish product **4**. Similar elimination has been observed in the reaction of imidazoles **2** with phenylsulfonylacetonitrile and a catalytic amount of DBU²¹ (Scheme 1).

In the literature, the reaction of formamidines **1** with active methylenes has been described.²² However, to our knowledge their reaction with ethyl acetoacetate has not yet been reported. A mixture of equimolar amounts of ethyl acetoacetate and **1a** reacted in the presence of DBU to form a product for which structure **6a** was proposed (Scheme 2).



Scheme 2

Although the spectroscopic features of the collected needles were very similar to those of 6-carbamoylpurines,^{17,19,22,23} an X-ray crystal structure analysis was carried out to confirm the structure of the product (Figure 1).





Figure 1. Molecular structure of 9-(4-methoxyphenyl)-2-methyl-9*H*-purine-6-carboxamide monohydrate **6a**

The isolation of 6-purinecarboxamide monohydrate **6a** suggests that the first step in the reaction is the conversion of formamidine **1a** to imidazole **2a**.¹² A mechanism of 6-carbamoylpurines **6** formation from imidazoles **2** has been described previously.^{22,23}

Alternatively, the reaction may proceed by a nucleophilic attack of the imino function on the acetyl group. Then, an elimination of water molecule occurs to yield **9** that undergoes a rapid loss of an ethyl acetate molecule, followed by basic hydrolysis of the cyano function to furnish **6** (**Scheme 3**).



Scheme 3

An attempt to diazotize imidazole **2a** to form imidazotriazines **11** using previously described procedure, resulted only in recovering the starting material.²⁴ Nevertheless, when a large excess of NaNO_2 and concentrated HCl were used, red crystals were isolated. The ^1H NMR spectrum of the crystals revealed the presence of a singlet for one proton at δ 4.58 ppm which was D_2O exchangeable, a base peak at m/z 252 appeared in the MS, also the IR showed a band at 1712 cm^{-1} which indicates the presence of a carbonyl group. In order to establish the structure of these crystals, X-ray was carried out and showed the product to be 4-carboxy-5-chloro-1-(4-methoxyphenyl)imidazolidinium chloride **12** which resulted from a nucleophilic aromatic substitution reaction (**Figure 2**).






Figure 2. Molecular structure of 4-carboxy-5-chloro-1-(4-methoxyphenyl)imidazolidinium chloride **12**

Diazotization was also performed on imidazoles **2b,c** utilising the same conditions used to diazotize imidazole **2a**; small amount of red crystals were collected. The ^1H NMR and MS spectra of these crystals, on the other hand, showed a different pattern than expected. Careful examination of the spectroscopic analyses of the obtained crystals enabled us to identify the products to be (1-aryl-5-hydroxy-1*H*-imidazol-4-yl)iminoacetonitrile **13b** (Ar = 4-MeC₆H₄) and **13c** (Ar = 4-ClC₆H₄) (**Scheme 4**).



Scheme 4

The yields in both reactions were low [**12** (40%), **13b** (30%) and **13c** (40%)], and all attempts to increase the yields were unsuccessful. Although the same conditions were utilised for imidazoles **2a,b** and **c**, it appears that two different S_NAr reactions operate. This might be due to the difference in the electronic effect of the methyl, chloro and methoxy substituents (**Scheme 5**).



Scheme 5

CONCLUSION

In conclusion, the reactive unit in (5-amino-1-aryl-1*H*-imidazol-4-yl)iminoacetonitrile could be converted into another reactive site simply by treating it with hydroxylamine hydrochloride. These imidazoles were shown to be valuable precursors for the synthesis of novel purines when reacted with triethyl orthoesters. In addition, reactions of formamidines with ethyl acetoacetate in the presence of DBU furnishes 6-carbamoylpurines. Also, two different S_NAr reactions took place *via* the diazotization of (5-amino-1-aryl-1*H*-imidazol-4-yl)iminoacetonitrile.

EXPERIMENTAL

General

Formamidines **1a-c** and imidazoles **2a,b** were prepared according to literature procedures.¹² Percentage yields calculated for (**4a,b**, **5a-f**, **6a,b**, **12** and **13b,c**) are based on 1.0 g of starting material. ¹H NMR spectra were recorded on a Bruker DPX 400 spectrometer at 400 MHz. CDCl₃ or DMSO-*d*₆ as a solvent and tetramethylsilane (TMS) as an internal standard; chemical shifts are reported in δ units (ppm). ¹³C NMR spectra were obtained using a Bruker DPX 400 spectrometer at 100 MHz. Mass spectra were recorded on a VG autospec Q spectrometer with a digital data output. IR was recorded on RT-IR Perkin Elmer System 2000, using KBr disc and ($\nu_{\max}$) was recorded in cm⁻¹. Melting points were determined by using a Gallenkamp melting point apparatus and are uncorrected. TLC was performed on a 0.25 mm pre-coated silica gel plates (Merck).

General procedure for preparation of Imidazole 2c

A suspension of formamidine **1c** (Ar = 4-ClC₆H₄) (5.00 mmol) and DBU (1 mL, 6.70 mmol) in EtOH was stirred at room temperature for 1 h, the solid obtained was recrystallised from a mixture of hot EtOH/H₂O.

[5-*Amino-1-(4-chlorophenyl)-1H-imidazol-4-yl*]iminoacetonitrile **2c**: light yellow powder (0.88 g, 3.58 mmol, 88%), mp > 200 °C (decomp.) [C₁₁H₈N₅Cl requires: 245.0462; M 245. Found: accurate mass: 245.0462; m/z (EI) M⁺ 245, 57%, 138, 100%]; δ_H 400 MHz (DMSO-*d*₆, TMS), 6.76 (s, 2H, NH₂), 7.50 (s, 1H, CH), 7.55 (m, 2H, ArH); 7.65 (m, 2H, ArH), 11.16 (s, 1H, NH); δ_C 100 MHz (DMSO-*d*₆, TMS), 143.91, 143.02, 133.19, 132.72, 130.01, 129.91, 126.94, 116.31, 113.32; $\nu_{\max}$: (KBr) 3444, 3298, 2226, 1631, 1580, 1538, 1489, 1393, 1305, 1246, 1172, 1088, 1051, 915, 829 cm⁻¹.

General procedure for preparation of Imidazoles 4a,b

A mixture of hydroxylamine hydrochloride (5.0 equiv.) and sodium acetate (4.0 equiv.) was added to a

suspension of imidazole **2** (1.0 equiv.) in EtOH, while stirring. The stirring was continued overnight, and the solids obtained were recrystallised from a mixture of hot EtOH/H₂O.

5-Amino-N-hydroxy-1-(4-methoxyphenyl)-1H-imidazole-4-carboxamidine 4a: white crystalline solid (0.49 g, 1.98 mmol, 48%), mp 209-211 °C [C₁₁H₁₃N₅O₂ requires: 247.1063; M 247. Found: accurate mass: 247.1069; m/z (EI) M⁺ 247, 100%]; δ_{H} 400 MHz (DMSO-*d*₆, TMS), 3.82 (s, 3H, OCH₃), 5.23 (s, 2H, NH₂), 5.42 (s, 2H, NH₂), 7.09 (d, 2H, *J* 9.2 Hz, ArH), 7.32 (s, 1H, CH), 7.41 (d, 2H, *J* 9.2 Hz, ArH), 8.97 (s, 1H, OH); δ_{C} 100 MHz (DMSO-*d*₆, TMS), 159.24, 150.69, 137.00, 130.00, 128.32, 126.49, 115.24, 112.37, 55.97; ν_{max} : (KBr) 3442, 3335, 1645, 1617, 1516, 1305, 1255, 1181, 1023, 926, 838 cm⁻¹.

5-Amino-N-hydroxy-1-(p-tolyl)-1H-imidazole-4-carboxamidine 4b: white crystalline solid (0.74 g, 3.2 mmol, 60%), mp 225-227 °C [C₁₁H₁₃N₅O₂ requires: 231.1114; M 231. Found: accurate mass: 231.1115; m/z (EI) M⁺ 231 100%]; δ_{H} 400 MHz (DMSO-*d*₆, TMS), 2.38 (s, 3H, CH₃), 5.27 (s, 2H, NH₂), 5.42 (s, 2H, NH₂), 7.35 (m, 5H, ArH & CH), 8.97 (s, 1H, OH); δ_{C} 100 MHz (DMSO-*d*₆, TMS), 150.18, 137.36, 136.29, 132.61, 130.14, 129.41, 124.20, 112.21, 20.63; ν_{max} : (KBr) 3434, 3396, 3313, 3180, 2846, 1633, 1581, 1514, 1490, 1447, 1322, 1194, 932 cm⁻¹.

General procedure for preparation of Purines 5a-f

A suspension of imidazoles **4** (1 equiv.), and of triethyl orthoformate/acetate or propionate (12 equiv.) was either refluxed for 2 h (**5a**), or stirred at room temperature overnight (18-20 h) (**5a-f**). The solids formed were filtered.

9-(4-Methoxyphenyl)-1,9-dihydropurin-6-one oxime 5a (recrystallised from a mixture of hot EtOH/H₂O): white powder (0.50 g, 1.94 mmol, 48%), rt (0.62 g, 2.40 mmol, 60%), mp 274-276 °C (decomp.) [C₁₂H₁₁N₅O₂ requires: 257.0907; M 257. Found: accurate mass: 257.0907; m/z (EI) M⁺ 257, 100%]; δ_{H} 400 MHz (DMSO-*d*₆, TMS), 3.84 (s, 3H, OCH₃), 7.16 (d, 2H, *J* 6.8 Hz, ArH), 7.67 (d, 2H, *J* 6.8 Hz, ArH), 8.78 (s, 1H, CH), 8.81 (s, 1H, CH), 8.94 (s, 1H, NH), 9.70 (s, 1H, OH); δ_{C} 100 MHz (DMSO-*d*₆, TMS), 159.26, 148.77, 144.70, 144.14, 143.80, 126.57, 125.52, 119.15, 114.80, 55.64; ν_{max} : (KBr) 3423, 3279, 3075, 1703, 1520, 1260, 1192, 1177, 1031, 972, 827 cm⁻¹.

9-(4-Methoxyphenyl)-2-methyl-1,9-dihydropurin-6-one oxime 5b (recrystallised from a mixture of hot EtOH/H₂O): white powder (0.49 g, 1.80 mmol, 45%), mp 275 °C [C₁₃H₁₃N₅O₂ requires: 271.1064; M 271. Found: accurate mass: 271.1063; m/z (EI) M⁺ 271, 20%, 255, 100%]; δ_{H} 400 MHz (DMSO-*d*₆, TMS), 2.70 (s, 3H, CH₃), 3.85 (s, 3H, OCH₃), 7.17 (d, 2H, *J* 6.8 Hz, ArH), 7.67 (d, 2H, *J* 6.8 Hz, ArH), 8.72 (s, 1H, CH), 9.31 (s, 1H, NH), 9.91 (s, 1H, OH); δ_{C} 100 MHz (DMSO-*d*₆, TMS), 159.55, 154.20, 149.27,

143.38, 143.20, 127.27, 125.94, 118.39, 115.22, 56.04, 20.97; $\nu_{\max}$: (KBr) 3372, 3078, 3062, 1690, 1519, 1444, 1430, 1304, 1257, 1199, 1180, 1090, 1023, 840 cm^{-1} .

2-Ethyl-9-(4-methoxyphenyl)-1,9-dihydropurin-6-one oxime 5c (recrystallised from mixture of EtOH/H₂O/acetone): white powder (0.57 g, 2.0 mmol, 50%), mp 260 °C (decomp.) [C₁₄H₁₅N₅O₂ requires: 285.1220; M 285. Found: accurate mass: 285.1220; m/z (EI) M⁺ 285, 10%, 269, 100%]; δ_{H} 400 MHz (DMSO-*d*₆, TMS) 1.23 (t, 3H, *J* 7.2 Hz, -CH₂CH₃), 3.07 (q, 2H, *J* 7.2 Hz, -CH₂CH₃), 3.85 (s, 3H, OCH₃), 7.17 (d, 2H, *J* 8.8 Hz, ArH), 7.73 (d, 2H, *J* 9.2 Hz, ArH), 8.77 (s, 1H, CH), 9.31 (s, 1H, NH), 9.91 (s, 1H, OH); δ_{C} 100 MHz (DMSO-*d*₆, TMS), 159.62, 158.54, 149.90, 144.72, 143.82, 127.02, 125.77, 118.30, 115.22, 56.06, 26.19, 10.23; $\nu_{\max}$: (KBr) 3423, 2975, 1688, 1574, 1523, 1456, 1405, 1304, 1260, 1181, 1050, 1027, 926 cm^{-1} .

9-(p-Tolyl)-1,9-dihydropurin-6-one oxime 5d (recrystallised from mixture of EtOH/H₂O/acetone): white powder (0.52 g, 2.15 mmol, 50%), mp 315 °C [C₁₂H₁₂N₅O requires: 241.0958; M 241. Found: accurate mass: 241.0959; m/z (EI) M⁺ 241, 100%]; δ_{H} 400 MHz (DMSO-*d*₆, TMS), 2.39 (s, 3H, CH₃), 7.40 (d, 2H, *J* 7.6 Hz, ArH), 7.71 (d, 2H, *J* 8.0 Hz, ArH), 8.31 (br.s, 1H, NH), 8.72 (s, 1H, CH), 8.76 (s, 1H, CH), 9.20 (s, 1H, OH); δ_{C} 100 MHz (DMSO-*d*₆, TMS) 148.67, 144.53, 143.51, 138.11, 131.42, 130.06, 123.54, 119.26, 56.00, 20.68, 18.59; $\nu_{\max}$: (KBr) 3327, 3209, 3113, 1696, 1520, 1494, 1391, 1345, 1245, 1193, 1092, 812 cm^{-1} .

2-Methyl-9-(p-tolyl)-1,9-dihydropurin-6-one oxime 5e (recrystallised from mixture of EtOH/H₂O/acetone): white powder (0.51 g, 2.0 mmol, 50%), mp 275 °C (decomp.) [C₁₃H₁₃N₅O requires: 255.1114; M 255. Found: accurate mass: 255.1114; m/z (EI) M⁺ 255, 25%, 239, 100%]; δ_{H} 400 MHz (DMSO-*d*₆, TMS) 2.41 (s, 3H, CH₃), 2.70 (s, 3H, CH₃), 7.44 (d, 2H, *J* 8 Hz, ArH), 7.67 (d, 2H, *J* 8.4 Hz, ArH), 8.78 (s, 1H, CH), 9.35 (s, 1H, NH), 9.95 (s, 1H, OH); δ_{C} 100 MHz (DMSO-*d*₆, TMS), 154.40, 149.23, 143.55, 143.10, 138.33, 131.41, 130.14, 123.92, 118.23, 20.73, 20.68; $\nu_{\max}$: (KBr) 3384, 3262, 3100, 1673, 1521, 1396, 1317, 1244, 1207, 1188, 1145, 971, 814 cm^{-1} .

2-Ethyl-9-(p-tolyl)-1,9-dihydropurin-6-one oxime 5f (recrystallised from a mixture of hot EtOH/H₂O): white powder (0.52 g, 1.93 mmol, 45%), mp 270 °C (decomp.) [C₁₄H₁₅N₅O requires: 269.1271; M 269. Found: accurate mass: 269.1273; m/z (EI) M⁺ 269, 12%, 252, 100%]; δ_{H} 400 MHz (DMSO-*d*₆, TMS), 1.24 (t, 3H, *J* 7.2 Hz, -CH₂CH₃), 2.40 (s, 3H, CH₃), 2.99 (q, 2H, *J* 7.2 Hz, -CH₂CH₃), 3.85 (s, 3H, OCH₃), 7.42 (d, 2H, *J* 8.4 Hz, ArH), 7.76 (d, 2H, *J* 8.4 Hz, ArH), 8.82 (s, 1H, CH), 9.33 (s, 1H, NH), 9.94 (s, 1H, OH); δ_{C} 100 MHz (DMSO-*d*₆, TMS), 157.46, 149.14, 142.93, 138.04, 131.66, 130.15, 123.38, 116.11,

79.26, 25.71, 20.71, 9.88; $\nu_{\max}$: (KBr) 3382, 3108, 1672, 1594, 1523, 1399, 1341, 1208, 1188, 1142, 968, 869, 812 cm^{-1} .

General procedure for preparation of Purines 6a,b

A mixture ethyl acetoacetate (5 equiv.) and DBU (1.6 equiv.) was stirred in an ice bath. To this, a suspension of formamidines **1a** (1.00 g, 4.14 mmol), **1b** (1.00 g, 4.44 mmol) in EtOH (8 mL) was added. The stirring was continued for 2 h in an ice bath, and 18 h at room temperature. The formed precipitates were filtered off, and recrystallised from EtOH (**6a**) and a mixture of EtOH/H₂O (**6b**).

9-(4-Methoxyphenyl)-2-methyl-9H-purine-6-carboxamide monohydrate 6a: colourless needles (0.81 g, 2.65 mmol, 65%), mp 270-273 °C [C₁₄H₁₅N₅O₃. Anal. Calcd for CHN: C, 55.81; H, 4.98; N, 23.25. Found: C, 55.85; H, 5.01; N, 23.11; m/z (EI) (M-H₂O)⁺ 283, 100%; M 301]; δ_{H} 400 MHz (DMSO-*d*₆, TMS), 2.74 (s, 3H, CH₃), 3.85 (s, 3H, OCH₃), 7.16 (d, 2H, *J* 9.8 Hz, ArH), 7.74 (d, 2H, *J* 9.8 Hz, ArH), 8.09 (s, 1H, NH), 8.38 (s, 1H, NH), 8.94 (s, 1H, CH); δ_{C} 100 MHz (DMSO-*d*₆, TMS) 164.88, 161.84, 159.49, 154.05, 148.35, 147.01, 129.54, 127.41, 126.03, 115.19, 56.04, 26.09; $\nu_{\max}$: (KBr) 3461, 3394, 3121, 1699, 1671, 1650, 1579, 1519, 1408, 1388, 1254, 1229, 1182, 1028, 956, 836 cm^{-1} .

2-Methyl-9-(p-tolyl)-9H-purine-6-carboxamide monohydrate 6b: white solid (0.96 g, 3.36 mmol, 76%), mp 275-277 °C [C₁₄H₁₅N₅O₂ requires: accurate mass 267.1114; M 285. Found: accurate mass (M-H₂O): 267.1116; m/z (EI) (M-H₂O)⁺ 267, 45%, 224, 100%]; δ_{H} 400 MHz (DMSO-*d*₆, TMS) 2.42 (s, 3H, CH₃), 2.75 (s, 3H, CH₃), 7.44 (d, 2H, *J* 8 Hz, ArH), 7.46 (d, 2H, *J* 8.4 Hz, ArH), 8.10 (s, 1H, NH), 8.38 (s, 1H, NH), 9.01 (s, 1H, CH); δ_{C} 100 MHz (DMSO-*d*₆, TMS), 164.89, 161.89, 153.93, 148.54, 146.81, 138.35, 132.17, 130.48, 129.67, 124.19, 26.13, 21.14; $\nu_{\max}$: (KBr) 3452, 1710, 1574, 1521, 1398, 1336, 1290, 1228, 1203, 957 cm^{-1} .

General procedure for the Synthesis of imidazolidinium chloride 12 and imidazoles 13b and 13c

A suspension of imidazoles **2** (0.50 g, 2.1 mmol) and 4 N HCl (20 mL) was heated gently, and then cooled in an ice bath. A cold solution of NaNO₂ (2.5 g, 36.0 mmol) was then added dropwise to the imidazole suspension. After the addition, stirring was continued in an ice bath for 30-45 min. The solution was warmed up for 15 min and stirred at room temperature overnight. The solid obtained was filtered and crystallised using a mixture of (acetone/hexane) for **12** using Vapour Diffusion Technique (VDT) and acetone for **13b,c**.

4-Carboxy-5-chloro-1-(4-methoxyphenyl)imidazolidinium chloride 12: red crystals (0.47 g, 1.60 mmol, 40%), mp 230-232 °C [C₁₁H₁₀N₂O₃Cl₂ (M-HCl). Anal. Calcd for CHN: C, 52.27; H, 3.56; N, 11.08.

Found: C, 52.34; H, 3.70; N, 11.16; requires accurate mass 252.0296, Found accurate mass (M-HCl): 252.0293; m/z (EI) (M-HCl)⁺ 252, 100%, M 289]; δ_H 400 MHz (DMSO-*d*₆, TMS), 3.84 (s, 3H, OCH₃), 4.58 (s, 1H, NH), 7.13 (d, 2H, *J* 8.8 Hz, ArH), 7.46 (d, 2H, *J* 8.8 Hz, ArH), 8.25 (s, 1H, CH); δ_C 100 MHz (DMSO-*d*₆, TMS) 162.42, 160.50, 138.52, 128.39, 127.43, 126.57, 124.36, 115.18, 56.06; $\nu_{\max}$: (KBr), 3423, 3117, 1712, 1607, 1535, 1510, 1437, 1384, 1304, 1256, 1175, 1021, 956, 848 cm⁻¹.

[5-Hydroxy-1-(*p*-tolyl)-1*H*-imidazol-4-yl]iminoacetoneitrile **13b**: red crystals (0.30 g, 1.32 mmol, 30%), mp 220 °C (decomp.) [C₁₂H₁₀N₄O Anal. Calcd for CHN: C, 63.71; H, 4.42; N, 24.77; M 226. Found: C, 63.79; H, 4.56; N, 24.48; m/z (EI) (M)⁺ 226, 100%]; δ_H 400 MHz (DMSO-*d*₆, TMS), 2.40 (s, 3H, CH₃), 4.58 (s, 1H, NH), 7.73 (s, 4H, Hz, ArH), 7.54 (s, 1H, CH), 7.56 (s, 1H, NH), 8.33 (s, 1H, OH); δ_C 100 MHz (DMSO-*d*₆, TMS) 155.47, 150.27, 138.99, 136.01, 130.39, 130.13, 125.43, 121.35, 114.82, 20.66; $\nu_{\max}$: (KBr) 3445, 3286, 1636, 1624, 1546, 1514, 1503, 1471, 1395, 1284, 1168, 922 cm⁻¹.

[1-(4-Chlorophenyl)-5-hydroxy-1*H*-imidazol-4-yl]iminoacetoneitrile **13c**: red crystals (0.40 g, 1.62 mmol, 40%), mp > 200 °C (decomp.) [C₁₁H₇N₄OCl. Anal. Calcd for CHN: C, 53.54; H, 2.83; N, 22.71; M 246. Found: C, 53.30; H, 2.83; N, 22.56; m/z (EI) (M)⁺ 246, 100%]; δ_H 400 MHz (DMSO-*d*₆, TMS), 7.55 (m, 3H, ArH and NH), 7.65 (m, 4H, ArH, CH & OH); δ_C 100 MHz (DMSO-*d*₆, TMS), 155.50, 150.39, 135.80, 133.97, 131.65, 129.97, 127.94, 121.27, 114.88; $\nu_{\max}$: (KBr) 3431, 3145, 2363, 1634, 1553, 1494, 1391, 1172, 1097m, 923 cm⁻¹.

Crystal data and structure refinement for **6a**.²⁵

Chemical formula (moiety) C₁₄H₁₅N₅O₃, chemical formula (total) C₁₄H₁₅N₅O₃, formula weight 301.31, temperature 150(2) K, radiation, wavelength MoK α , 0.71073 Å, crystal system, space group monoclinic, P2₁/c, unit cell parameters *a* = 13.238(3) Å, α = 90°, *b* = 10.059(2) Å, β = 107.757(16)°, *c* = 10.7144(8) Å, γ = 90°, cell volume 1358.7(4) Å³, *Z* 4, calculated density 1.473 g/cm³, absorption coefficient μ 0.108 mm⁻¹, *F*(000) 632, crystal colour and size colourless, 0.45 × 0.40 × 0.40 mm³, reflections for cell refinement 285 (θ range 2.5 to 27.5°), data collection method, Nonius KappaCCD diffractometer ϕ and ω scans, θ range for data collection 4.0 to 27.5°, index ranges *h* -17 to 17, *k* -13 to 12, *l* -13 to 13, completeness to θ = 26.0°, 99.4%, reflections collected 12996, independent reflections 3087 (*R*_{int} = 0.0234), reflections with *F*² > 2 σ 2608, absorption correction semi-empirical from equivalents, min. and max. transmission, 0.953 and 0.958, structure solution direct methods, refinement method full-matrix least-squares on *F*², weighting parameters *a*, *b* 0.0372, 0.7683, data/restraints/parameters 3087/0/ 217, final *R* indices [*F*² > 2 σ] *R*1 = 0.0355, *wR*2 = 0.0840, *R* indices (all data) *R*1 = 0.0465, *wR*2 = 0.0910,

goodness-of-fit on F^2 1.034, largest and mean shift/su 0.000 and 0.000, largest diff. peak and hole 0.31 and $-0.22 \text{ e } \text{\AA}^{-3}$.

*Crystal data and structure refinement for 12.*²⁶

Chemical formula (moiety) $\text{C}_{11}\text{H}_{10}\text{ClN}_2\text{O}_3^+ \cdot \text{Cl}^-$, chemical formula (total) $\text{C}_{11}\text{H}_{10}\text{Cl}_2\text{N}_2\text{O}_3$, formula weight 289.11, temperature 150(2) K, radiation, wavelength $\text{MoK}\alpha$, 0.71073 $\text{\AA}$, crystal system, space group monoclinic, $\text{P2}_1/\text{c}$, unit cell parameters $a = 12.3041(18) \text{ \AA}$, $\alpha = 90^\circ$, $b = 7.3244(18) \text{ \AA}$, $\beta = 94.266(10)^\circ$, $c = 13.4882(10) \text{ \AA}$, $\gamma = 90^\circ$, cell volume $1212.2(4) \text{ \AA}^3$, Z 4, calculated density 1.584 g/cm^3 , absorption coefficient μ 0.536 mm^{-1} , $F(000)$ 592, crystal colour and size red, $0.45 \times 0.30 \times 0.30 \text{ mm}^3$, reflections for cell refinement 180 (θ range 2.5 to 27.5°), data collection method Nonius KappaCCD diffractometer ϕ and ω scans, θ range for data collection 4.1 to 27.5° , index ranges h -15 to 15 , k -9 to 9 , l -17 to 17 , completeness to $\theta = 26.0^\circ$ 99.5%, reflections collected 13774, independent reflections 2776 ($R_{\text{int}} = 0.0278$), reflections with $F^2 > 2\sigma$ 2340, absorption correction semi-empirical from equivalents, min. and max. transmission 0.795 and 0.855, structure solution direct methods, refinement method Full-matrix least-squares on F^2 , weighting parameters a , b 0.0388, 1.1248, data/restraints/parameters 2776/0/172, final R indices [$F^2 > 2\sigma$] $R1 = 0.0313$, $wR2 = 0.0861$, R indices (all data) $R1 = 0.0415$, $wR2 = 0.0929$, goodness-of-fit on F^2 1.128, extinction coefficient 0.0000(12), largest and mean shift/su 0.001 and 0.000, largest diff. peak and hole 0.50 and $-0.30 \text{ e } \text{\AA}^{-3}$.

ACKNOWLEDGMENTS

The financial support of Kuwait University received through research grant SC 01/07 and SAF facilities through projects GS 01/01 and GS 03/01 are gratefully acknowledged. Thanks are due to Professor W. Clegg at the University of Newcastle upon Tyne, UK, for providing X-ray crystallographic results.

REFERENCES

1. J. H. Lister, in *The Chemistry of Heterocyclic Compounds*, vol. 24 (II); *Fused Pyrimidines*, Part II, *Purines*, ed. by E. C. Taylor and A. Weissberger, Wiley-Interscience, New York, 1971, 380-382.
2. K. T. Potts, in *Comprehensive Heterocyclic Chemistry*, ed. by A. R. Katritzky and C. W. Rees, Pergamon Press, 1984, **5**, 548-549.
3. C. A. Ramsden, in *Comprehensive Heterocyclic Chemistry II*, ed. by A. R. Katritzky, C. W. Rees, and E. F. V. Scriven, Pergamon, 1996, **7**, 414.
4. A. Al-Azmi, B. L. Booth, R. A. Carpenter, A. Carvalho, E. Marrelec, R. G. Pritchard, and F. J. R. P. Proença, *J. Chem. Soc., Perkin Trans. 1*, 2001, 2532.

5. M. A. Carvalho, T. M. Esteves, M. F. Proença, and B. L. Booth, *Org. Biorg. Chem.*, 2004, **2**, 1019.
6. a) M. A. Carvalho, S. Esperança, T. M. Esteves, and M. F. Proença, *Eur. J. Org. Chem.*, 2007, 1324; b) M. J. Alves, B. L. Booth, M. A. Carvalho, R. G. Pritchard, and F. J. R. P. Proença, *J. Heterocycl. Chem.*, 1997, **34**, 913.
7. M. Hocek, M. Masojdkova, A. Holy, A. Graciela, R. Snoeck, J. Balzarini, and E. DeClerq, *Collect. Czech. Chem. Commun.*, 1996, **61**, 1525.
8. T. E. Mabry, C. D. Jones, T. S. Chou, J. M. Colacino, G. B. Grindey, J. F. Worzalla, and H. L. Pearce, *Nucleosides Nucleotides*, 1994, **13**, 1125.
9. J. L. Kelley, D. C. Wilson, V. L. Styles, F. S. Soroko, and B. R. Cooper, *J. Heterocycl. Chem.*, 1995, **32**, 1417.
10. A. Al-Azmi, P. George, and O. M. E. El-Dusouqui, *J. Heterocycl. Chem.*, 2007, **44**, 515.
11. W. Pendergast and W. R. Hall, *J. Heterocycl. Chem.*, 1989, **26**, 1863.
12. A. Al-Azmi, A. Elassar, and B. L. Booth, *Tetrahedron*, 2003, **59**, 2749.
13. A. Al-Azmi, *J. Chem. Res.*, 2005, **8**, 530.
14. A. Al-Azmi, B. L. Booth, R. G. Pritchard, and F. J. R. P. Proença, *J. Chem. Soc., Perkin Trans. I*, 2001, 485.
15. M. J. Alves, B. L. Booth, M. A. Carvalho, R. G. Pritchard, and F. J. R. P. Proença, *J. Heterocycl. Chem.*, 1997, **34**, 739.
16. M. J. Alves, B. L. Booth, M. A. Carvalho, A. M. Dias, and M. F. Proença, *J. Chem. Res. (S)*, 1996, 212, *J. Chem. Res. (M)*, 1996, 1101.
17. B. L. Booth, A. M. Dias, and M. F. Proença, *J. Chem. Soc., Perkin Trans. I*, 1992, 2119.
18. M. J. Alves, B. L. Booth, and M. F. Proença, *J. Chem. Soc., Perkin Trans. I*, 1990, 1705.
19. M. J. Alves, B. L. Booth, A. P. Freitas, and M. F. Proença, *J. Chem. Soc., Perkin Trans. I*, 1992, 913.
20. A. P. Freitas, M. F. Proença, and B. L. Booth, *J. Heterocycl. Chem.*, 1995, **32**, 457.
21. M. E. A. Zaki and M. F. Proença, *Tetrahedron*, 2007, **63**, 3745.
22. M. E. A. Zaki, M. F. Proença, and B. L. Booth, *J. Org. Chem.*, 2003, **6**, 276.
23. M. E. A. Zaki, M. F. Proença, and B. L. Booth, *Synlett*, 2005, **16**, 2429.
24. A. Al-Azmi, P. George, and O. M. E. El-Dusouqui, *Heterocycles*, 2007, **71**, 2183.
25. Crystal data for compound **6a**: (ref. CCDC 695454) can be obtained on request from the Director, Cambridge Crystallographic Data Centre, 12 Union Road, Cambridge CB2 1EW, UK. CCDC.
26. Crystal data for compound **12**: (ref. CCDC 695453) can be obtained on request from the Director, Cambridge Crystallographic Data Centre, 12 Union Road, Cambridge CB2 1EW, UK. CCDC.